两步临床路径预测2型糖尿病MASLD相关进展性纤维化及长期结局
该研究评估指南推荐的FIB-4序贯VCTE肝硬度检测两步法,在2型糖尿病MASLD患者中预测进展性纤维化和肝脏相关事件。活检队列(n=352)显示正确分类率71%,VCTE预后队列(n=4429)5年累积肝脏相关事件发生率在低、中、高危组分别为0.7%、0.9%和11.8%。采用LSM 10和15 kPa界值可进一步优化风险分层。
要点
- FIB-4序贯LSM两步法可有效分层2型糖尿病MASLD患者的进展性纤维化和肝脏相关事件风险
- 活检队列中22.2%存在进展性纤维化,两步法正确分类率71%
- VCTE预后队列5年肝脏相关事件累积发生率低危0.7%、中危0.9%、高危11.8%
核心结论
- FIB-4序贯LSM的非侵入性两步法能有效分层2型糖尿病MASLD患者的进展性纤维化和肝脏相关事件风险。
- 采用LSM 10和15 kPa界值可进一步优化未来肝脏相关事件的风险分层。
研究设计与样本
- 前瞻性肝活检队列:中国7个中心、组织学确诊MASLD的2型糖尿病患者352例,其中22.2%有进展性纤维化,用于评估诊断效能。
- 国际VCTE-Prognosis队列:美国、欧洲和亚洲16个中心接受VCTE的2型糖尿病MASLD患者4429例,纵向随访,用于评估肝脏相关事件。
主要发现
- 肝活检队列中,FIB-4后应用LSM<8 kPa和>12 kPa界值,将患者分为低危63.4%、中危9.4%、高危27.3%,正确分类率71%。
- VCTE-Prognosis队列中位随访51.3个月(IQR 27.4-70.7),140例(3.2%)发生肝脏相关事件,其中110例(2.5%)为肝功能失代偿,59例(1.3%)为肝细胞癌。
- 两步法将72.6%、6.8%和20.6%的患者分为低危、中危和高危组,对应5年累积肝脏相关事件发生率分别为0.7%、0.9%和11.8%。
- 对FIB-4中危患者采用LSM<10 kPa(低危)和>15 kPa(高危)重新分类,使中危组降至5.6%,同时保持预测准确性。
关键数值与推荐
- 两步法第一步为FIB-4,第二步为VCTE肝硬度测量。
- 肝活检队列中LSM界值:<8 kPa和>12 kPa用于风险分层。
- VCTE-Prognosis队列中优化界值:LSM<10 kPa为低危,>15 kPa为高危。
临床怎么用
- 对2型糖尿病合并MASLD患者,可先计算FIB-4,再对需要者行VCTE肝硬度检测以分层进展性纤维化和肝脏相关事件风险。
- 可考虑采用LSM 10和15 kPa界值优化中危患者的风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend a two-step approach for risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD), starting with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE). OBJECTIVE: To evaluate this approach for predicting advanced fibrosis and liver-related events (LREs) in patients with type 2 diabetes (T2D). DESIGN: A prospective liver biopsy cohort of T2D patients with histologically confirmed MASLD from seven centres in China was used to assess diagnostic performance for advanced fibrosis. The international VCTE-Prognosis cohort, including T2D patients with MASLD who underwent VCTE at 16 centres in the USA, Europe and Asia, with longitudinal follow-up, was used to assess LREs, defined as hepatic decompensation or hepatocellular carcinoma. RESULTS: 4781 participants were included. In the liver biopsy cohort (n=352; 22.2% with advanced fibrosis), applying LSM thresholds of <8 kPa and >12 kPa after FIB-4 classified patients into 63.4% low-risk, 9.4% intermediate-risk and 27.3% high-risk, with a correct classification rate of 71%. In the VCTE-Prognosis cohort (n=4429; median follow-up 51.3 (IQR 27.4-70.7) months), 140 (3.2%) patients developed LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of patients into low-risk, intermediate-risk and high-risk groups, with corresponding 5-year cumulative LRE incidences of 0.7%, 0.9% and 11.8%. Refining classification of intermediate FIB-4 patients using LSM <10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk group to 5.6% while preserving predictive accuracy. CONCLUSION: The non-invasive two-step approach of FIB-4 followed by LSM effectively stratifies MASLD-related advanced fibrosis and LREs risk in T2D. Applying LSM cut-offs of 10 and 15 kPa further optimises risk stratification for future LREs.
引用
- Chen Y, Dong B, Jin X, et al. Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes. Gut. 2026. PMID: 41911049. doi:10.1136/gutjnl-2025-337506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。